drugset / Trial / NCT06999434
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Phase 1
Recruiting
105 enrolled
Yale University
National Institute for Biomedical Imaging and Bioengineering (NIBIB) · collabNational Institute on Aging (NIA) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Timeline
- Start
- 2025-05-05
- Primary completion
- 2030-05-05
- Completion
- 2030-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F18-3F4AP | Diagnostic / imaging agent | — | — |
| Background | 11C-PiB | Diagnostic / imaging agent | — | — |
| Background | 18F-MK-6240 | Diagnostic / imaging agent | — | — |